Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cantor Fitzgerald
Teva
Colorcon
Chinese Patent Office
US Army
Dow
Merck
UBS
Julphar

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,410,077

« Back to Dashboard

Which drugs does patent 8,410,077 protect, and when does it expire?


Patent 8,410,077 protects EVOMELA, CARNEXIV, and NOXAFIL, and is included in three NDAs. There have been zero Paragraph IV challenges on Evomela and Noxafil

This patent has twenty-one patent family members in thirteen countries.

Summary for Patent: 8,410,077

Title:Sulfoalkyl ether cyclodextrin compositions
Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Inventor(s): Antle; Vincent (Olathe, KS)
Assignee: CyDex Pharmaceuticals, Inc. (La Jolla, CA)
Application Number:12/613,103
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Device; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Spectrum PharmsEVOMELAmelphalan hydrochloridePOWDER;IV (INFUSION)207155-001Mar 10, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Lundbeck Pharms LlcCARNEXIVcarbamazepineSOLUTION;IV (INFUSION)206030-001Oct 7, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Merck Sharp DohmeNOXAFILposaconazoleSOLUTION;IV (INFUSION)205596-001Mar 13, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,410,077

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,635,773Sulfoalkyl ether cyclodextrin compositions► Subscribe
9,750,822Sulfoalkyl ether cyclodextrin compositions► Subscribe
9,200,088Sulfoalkyl ether cyclodextrin compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,410,077

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20110010742► Subscribe
Japan2017019879► Subscribe
Japan2012072160► Subscribe
Japan2010539193► Subscribe
Japan6039721► Subscribe
Japan4923144► Subscribe
Japan2015110671► Subscribe
Israel208956► Subscribe
European Patent Office2268269► Subscribe
Hong Kong1219883► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Daiichi Sankyo
Chubb
McKesson
US Department of Justice
Citi
Medtronic
AstraZeneca
Teva
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot